SLC5A2 and diabetes mellitus: Evidence of cardiovascular benefit with these agents led to the undertaking of large cardiovascular outcome trials, which have consistently shown a reduction in the composite of cardiovascular mortality or HF hospitalizations with SGLT2 inhibitors in patients with diabetes [8], [9], [10], [11], [12], [13], [14], [15].